Skip to main content
    While there wasn’t much original new programming and research presented on the final day, that didn’t slow the RheumNow faculty from tweeting the noteworthy “Best of ACR” abstracts. Enjoy these below.
    Since chronic kidney disease is one of the strongest CV risk factors, any new strategy to reduce proteinuria and avoid a decline in renal function may likely improve patient outcomes. In large cardiovascular outcome trials, the use of a fairly new-kid-on-the-block therapy, sodium–glucose cotransporter-2 inhibitors (SGLT2i) appear to be both cardio and renal-protective. Would the use of SGLT2i have the same impact in SLE?
    The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations.  Here’s a list of the late breakers; below, I provide commentary on the ones that caught my attention.
    #ACRbest Abstracts – Day 2

    Our reporters have been prolific in finding the hot abstracts, those that were most atten

    Dr. John Cush RheumNow

    3 months ago
    #ACRbest Abstracts – Day 2 Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract reports from Monday, 11/13 at #ACR23. https://t.co/yIYYI7IVBD https://t.co/86Nt1mVha8
    Lupus Topic Panel

    Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most intere

    Dr. John Cush RheumNow

    3 months ago
    Lupus Topic Panel Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most interesting lupus studies presented at #ACR23. https://t.co/QWR17kOkHD https://t.co/jpaUI2X2Fc
    Methotrexate: shall we split up?

    Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance is

    Dr. John Cush RheumNow

    3 months ago
    Methotrexate: shall we split up? Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. https://t.co/txCIkgtvzP https://t.co/Mk8FLy4jO3